Introduction
Understanding the manufacturer of a prescription medicine is an important part of pharmaceutical product verification. Manufacturer information helps patients, healthcare professionals, pharmacists and medicine distributors identify the organization responsible for producing a particular product.
Alecnib is identified as a product containing alectinib 150 mg, a targeted anticancer medicine used in specified patients with ALK-positive non-small cell lung cancer (NSCLC).
Although the active ingredient is identified as alectinib, the manufacturer of the specific Alecnib product has not been independently verified through official product documentation. Therefore, this page does not assign Alecnib to a particular pharmaceutical company without supporting evidence.
It is important to distinguish the company that originally developed a medicine from the company that manufactures a particular branded product. These organizations may be different.
This page explains the pharmaceutical background of alectinib, the established reference medicine, the role of its associated companies and the information that should be checked to establish the manufacturer of Alecnib.
Who Developed Alectinib?
Alectinib is a targeted anticancer medicine developed for the treatment of cancers involving abnormal anaplastic lymphoma kinase (ALK) signaling.
The established reference brand Alecensa is associated with Roche and Genentech in relevant markets. The medicine was developed as part of the advancement of targeted cancer treatment for patients whose tumors contain specific molecular abnormalities.
Alectinib belongs to the ALK tyrosine kinase inhibitor class. It works by blocking abnormal ALK signaling pathways that can contribute to cancer-cell growth and survival.
Its development represents an important step in precision oncology, where treatment selection is based on the molecular characteristics of a patient’s cancer.
The development and commercialization of alectinib involved clinical research, pharmaceutical development, regulatory evaluation and manufacturing processes.
However, the companies associated with the reference medicine should not automatically be identified as the manufacturer of Alecnib.
The Reference Medicine: Alecensa
Alecensa is an established reference brand containing alectinib.
Alecensa is used for specified patients with ALK-positive NSCLC. Its approved indications vary according to the country and applicable regulatory authorization.
In the United States, the reference product has indications for qualifying adults following surgical resection of ALK-positive NSCLC and for adults with metastatic ALK-positive NSCLC.
Alecensa is supplied in 150 mg capsules in its established formulation. Its U.S. reference-product dosage regimen for adults is 600 mg twice daily with food, subject to the prescribing information and individual clinical assessment.
The reference product’s manufacturer and regulatory information can help readers understand the established pharmaceutical background of alectinib. It does not establish the identity, origin or authorization of a separate brand such as Alecnib.
Understanding the Different Pharmaceutical Roles
Several organizations may be involved in developing, producing and distributing a medicine. Their responsibilities should not be confused.
1. Medicine developer
The developer is the organization involved in discovering or developing the active pharmaceutical ingredient or the original medicine.
Development may involve:
- Identifying a therapeutic target.
- Researching the active ingredient.
- Conducting laboratory studies.
- Performing preclinical investigations.
- Organizing clinical trials.
- Evaluating effectiveness and safety.
- Preparing regulatory submissions.
A medicine developer may also hold rights to a reference product, but this does not mean that every product containing the same active ingredient is manufactured by that company.
2. Pharmaceutical manufacturer
The manufacturer is the company or manufacturing organization responsible for producing a specific medicine.
Its responsibilities may include:
- Pharmaceutical production.
- Quality-control testing.
- Batch documentation.
- Manufacturing-process validation.
- Packaging operations.
- Compliance with applicable good manufacturing practice requirements.
- Maintaining appropriate manufacturing records.
The manufacturer of Alecnib should be identified from the product’s actual packaging and official documentation.
3. Brand owner
A brand owner is the company or legal entity that owns or controls a particular commercial product name.
The brand owner may be different from the physical manufacturer.
For example, one company may own a medicine brand while another authorized organization performs the manufacturing or packaging.
4. Marketing authorization holder
The marketing authorization holder is the legal entity responsible for a medicine’s marketing authorization in a particular country or regulatory jurisdiction.
Its responsibilities depend on applicable pharmaceutical laws and may include maintaining regulatory documentation, reporting safety information and ensuring compliance with authorization requirements.
A marketing authorization in one country does not automatically establish authorization in another.
5. Distributor
A distributor is an organization involved in moving pharmaceutical products through the supply chain.
Distribution may involve storage, transportation, inventory management and supply to authorized pharmacies, hospitals or other permitted purchasers.
A distributor should not be described as the manufacturer unless it also has a verified manufacturing role.
6. Supplier
A supplier is an organization or commercial entity that provides a product through a particular purchasing or supply arrangement.
A supplier’s identity alone does not establish the medicine’s original manufacturer, brand ownership or regulatory status.
Alecnib Manufacturer Information
The following table summarizes the information currently identified for Alecnib.
| Product detail | Information |
|---|---|
| Product name | Alecnib |
| Active ingredient | Alectinib |
| Stated strength | 150 mg |
| Therapeutic category | Targeted anticancer medicine |
| Pharmacological class | ALK tyrosine kinase inhibitor |
| Reference brand | Alecensa |
| Reference-product company | Roche/Genentech |
| Alecnib manufacturer | Not independently verified |
| Alecnib brand owner | Not independently verified |
| Marketing authorization holder | Not independently verified |
| Manufacturing location | Not independently verified |
| Product registration | Requires country-specific verification |
This information is presented to avoid confusion between the established reference product and the specific Alecnib brand.
Pharmaceutical Quality and Manufacturing Standards
Manufacturing quality is essential for prescription anticancer medicines.
A pharmaceutical product should be manufactured under appropriate quality systems and comply with applicable regulatory requirements.
Good Manufacturing Practice (GMP) is a system designed to help ensure that medicines are consistently produced and controlled according to appropriate quality standards.
Important manufacturing considerations include:
Raw material quality: Pharmaceutical ingredients should meet established specifications for identity, purity and quality.
Production controls: Manufacturing processes should be appropriately documented and controlled.
Quality testing: Finished products should undergo appropriate testing before release.
Batch traceability: Manufacturing and packaging records should support the identification of individual batches.
Packaging integrity: Packaging should protect the medicine and provide accurate product information.
Storage requirements: Products should be stored and transported according to their approved conditions.
These standards are relevant to alectinib-containing products, but no specific GMP certification or manufacturing facility should be attributed to Alecnib without supporting documentation.
How to Identify the Manufacturer of Alecnib
Patients, pharmacists and healthcare professionals should review the actual product documentation when identifying a medicine’s manufacturer.
The following information may help:
- Product name: Confirm that the packaging identifies the product as Alecnib.
- Active ingredient: Check that alectinib is stated as the active pharmaceutical ingredient.
- Strength: Confirm the stated 150 mg strength.
- Dosage form: Check the dosage form printed on the package.
- Manufacturer’s name: Identify the legal company named as manufacturer.
- Manufacturing address: Review the stated manufacturing location.
- Batch number: Check the batch or lot identification.
- Expiry date: Confirm that the product is within its stated shelf life.
- Regulatory information: Review applicable registration or authorization details.
- Patient information leaflet: Compare the leaflet with the medicine’s packaging and official product documentation.
If any information is unclear or inconsistent, a pharmacist or appropriate regulatory authority should be consulted.
Why Manufacturer Transparency Matters
Manufacturer transparency helps establish the identity and origin of pharmaceutical products.
It is particularly important for anticancer medicines because patients may depend on consistent product quality and reliable supply.
Accurate manufacturer information can help support:
- Product identification.
- Supply-chain traceability.
- Quality assurance.
- Regulatory compliance.
- Pharmacovigilance reporting.
- Recall management.
- Responsible pharmaceutical distribution.
Incorrectly identifying a manufacturer can create confusion about product origin, regulatory authorization and accountability.
For this reason, Alecnib’s manufacturer should only be named when reliable product-specific evidence is available.
Is Alecnib Manufactured by the Same Company as Alecensa?
The manufacturer of Alecensa should not automatically be assumed to manufacture Alecnib.
Alecensa is an established reference brand containing alectinib. Alecnib is a separate brand name identified on this website.
Two medicines may contain the same active ingredient and strength but have different brand owners, manufacturers, packaging arrangements and regulatory authorizations.
To establish whether the products have any manufacturing relationship, their official product documentation must be compared.
Product Verification and Authenticity
Before using any prescription anticancer medicine, the product’s identity and source should be checked.
A package should not be considered authentic solely because it has professional-looking printing, a barcode, a QR code or a batch number.
Verification should involve appropriate documentation and, when necessary, confirmation from the manufacturer or relevant regulatory authority.
Patients should avoid using medicines when there are serious concerns about product identity, packaging integrity or supply-chain legitimacy.
Conclusion
Alecnib is identified as a 150 mg alectinib product associated with targeted treatment of ALK-positive non-small cell lung cancer.
Alecensa is an established reference brand containing alectinib and is associated with Roche and Genentech in relevant markets. However, this reference-product relationship does not independently establish the manufacturer of Alecnib.
The manufacturer, brand owner, marketing authorization holder and manufacturing location of Alecnib require product-specific verification.
Accurate manufacturer information is essential for pharmaceutical transparency, product identification and responsible medicine supply. Patients and healthcare professionals should always rely on official packaging and regulatory documentation when confirming the identity of a prescription medicine.